Medicus Pharma Ltd. MDCX
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · medicuspharma.com
Clinical-stage life-sciences company advancing SkinJect, a dissolvable microneedle patch for basal cell carcinoma, and Teverelix, a GnRH antagonist for acute urinary retention and prostate cancer, through Phase 2 studies.
Key ratios
ReturnOnAssets TTM -2.78
ReturnOnAssets 2025 -2.04
ReturnOnAssets 2024 -1.85
ReturnOnAssets 2023 -2.56
ReturnOnEquity TTM -28.65
ReturnOnEquity 2025 -29.81
ReturnOnEquity 2024 -5.25
Recent news
Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom
2026-08-03 · GlobeNewswire
Medicus Pharma Receives UAE Department of Health Authorization for Precision Medicine Study Evaluating Teverelix in Women with Endometriosis
2026-07-31 · GlobeNewswire